CN100337628C - Nimodipine oral disintegrant tablet for curing dementia and its preparation method - Google Patents

Nimodipine oral disintegrant tablet for curing dementia and its preparation method Download PDF

Info

Publication number
CN100337628C
CN100337628C CNB021254311A CN02125431A CN100337628C CN 100337628 C CN100337628 C CN 100337628C CN B021254311 A CNB021254311 A CN B021254311A CN 02125431 A CN02125431 A CN 02125431A CN 100337628 C CN100337628 C CN 100337628C
Authority
CN
China
Prior art keywords
nimodipine
gram
tablet
dementia
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB021254311A
Other languages
Chinese (zh)
Other versions
CN1394605A (en
Inventor
侯鹏
王登之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB021254311A priority Critical patent/CN100337628C/en
Publication of CN1394605A publication Critical patent/CN1394605A/en
Application granted granted Critical
Publication of CN100337628C publication Critical patent/CN100337628C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Abstract

The present invention relates to a nimodipine oral disintegrating tablet for treating dementia and a method for preparing the nimodipine oral disintegrating tablet. All the drugs for treating patients with dementia need to be taken with water in the prior art. The nimodipine oral disintegrating tablet is prepared from a main drug and auxiliary materials, wherein the auxiliary materials comprise four or eight raw materials made into freeze drying tablets or compressed tablets by two methods. The nimodipine oral disintegrating tablet has the advantages that patients can take the tablet without water, and the tablet can disintegrate in 5 seconds or 30 seconds in the oral cavity, so that patients can be treated in time, and the trouble for fetching water is omitted. The product of the nimodipine oral disintegrating tablet is used for treating senile dementia, hypertension, cerebrovascular diseases, migraine, cerebrovascular spasm, apoplexy, etc.

Description

Nimodipine oral disintegrant tablet of treatment dementia and preparation method thereof
Technical field
The present invention relates to pharmaceutical, particularly treat dementia and hypertensive Nimodipine oral disintegrant tablet, and preparation method thereof.
Background technology
People suffer from dementia, hypertension, ischemic cerebrovascular etc. when taking medicine, and must take medicine with boiled water.Take medicine when patient's water on the one hand, particularly old age and women and children patient are usually very inconvenient; Medicine can improve drug effect (bioavailability) widely and also play a role rapidly at the rapid disintegrate in oral cavity (common below 30 seconds) on the other hand.Therefore, medicine oral disintegrated preparation technology has become one of contemporary medical high-tech, is with a wide range of applications.
Summary of the invention
The object of the present invention is to provide a kind of taking medicine conveniently, the obvious results oral cavity disintegration tablet, and preparation method thereof.
Purpose of the present invention can reach by following measure.Treatment dementia and hypertensive Nimodipine oral disintegrant tablet are made up of principal agent and adjuvant, wherein:
One, principal agent: every contains 10 milligrams of nimodipine, 20 milligrams, 30 milligrams totally three kinds of specifications;
Two, adjuvant: mixture ratio by weight percent and raw material are formed, and according to preparation technology's difference, can adopt following two kinds of prescriptions:
(1) forms by four kinds of adjuvants
A) mannitol 5-80%
B) sucrose 5-80%
C) gelatin 0.1-10%
D) hydroxyethyl-cellulose 0.1-7.5%
(2) form by eight kinds of adjuvants
A) glucose 10-50%
B) compressibility sorbitol 10-50%
C) mannitol 10-40%
D) sucrose 10-40%
E) sodium bicarbonate 5-20%
F) citric acid 5-10%
G) saccharin sodium 0.05%
H) aspartame 0.05%.
The preparation method of the Nimodipine oral disintegrant tablet of treatment dementia is suspended in the principal agent nimodipine in the hydroxyethyl cellulose aqueous solution, forms solution A, press the prescription in the adjuvant (1),, form solution B gelatin, mannitol and sucrose mixed dissolution, solution A and solution B are mixed, and add an amount of water dilution, and abundant mixing, join sharp freezing in the mould, put into the freeze dryer evacuation, and subliming up into the material bone dry, press seal, packing are the lyophilizing sheet.
Another preparation method of Nimodipine oral disintegrant tablet of treatment dementia press prescription mix homogeneously in the adjuvant (2) to principal agent nimodipine and eight kinds of adjuvants, and adding wetting agent or binding agent are made soft material, sieve oven dry, granulate, tabletting, packing are compressed tablet behind the adding lubricant.
The present invention has following advantage compared to existing technology: with the disintegrating tablet that two kinds of preparation methoies make, all need not take medicine by water, put into the oral cavity with the lyophilizing sheet, disintegrate below 5 seconds.Use compressed tablet, disintegrate below 30 seconds in the oral cavity is taken medicine and is saved trouble, and saves the trouble with the water delivery service medicine, and treatment in time, and is effective.
Description of drawings
Fig. 1: nimodipine C 21H 26N 2O 7Molecular structure.
The specific embodiment
Enumerate three embodiment below, the present invention is further specified.
Embodiment 1
10 gram nimodipine are suspended in the 7.5 gram hydroxyethyl cellulose aqueous solutions, make solution A, then 2.5 gram gelatin, 25 gram sucrose and 65 gram mannitol mixed dissolutions, make solution B, solution A and solution B are mixed, add the suitable quantity of water mixing, put into the mould sharp freezing, evacuation in freeze dryer, and sublime up into the material bone dry, press seal, packing.
The gross weight of four kinds of adjuvants is 100 grams, makes 1000,100 milligrams of every adjuvants, and 10 milligrams of nimodipine of principal agent, promptly oral cavity disintegration tablet heavily is 110 milligrams, this sheet is the lyophilizing sheet.
Embodiment 2
20 gram nimodipine, 10 gram gelatin, 1 gram hydroxyethyl-cellulose, 15 gram mannitol and 74 gram sucrose replace to be implemented the raw material consumption in 1, method is with embodiment 1, the gross weight of four kinds of adjuvants is 100 grams, make 1000,100 milligrams of every adjuvants, 20 milligrams of nimodipine, promptly every heavy 120 milligrams, every contains 20 milligrams of nimodipine.
Embodiment 3
Glucose 30 grams, compressibility sorbitol 10 grams, mannitol 20 grams, sucrose 20 grams, sodium bicarbonate 10 grams, citric acid 9.9 grams, saccharin sodium 0.05 gram and aspartame 0.05 gram be totally eight kinds of adjuvant 100 grams, with nimodipine 30 gram mix homogeneously, add wetting agent and make soft material, sieve, oven dry, granulate, tabletting behind the adding lubricant is made 1000, every heavy 130mg, wherein nimodipine contains 30mg, and adjuvant 100mg, this sheet are compressed tablet.
When preparing this product, every sheet is heavy variable.
Product of the present invention is used for the treatment of senile dementia, mild or moderate hypertension, ischemic cerebrovascular, sudden deafness, migraine, subarachnoid hemorrhage and causes diseases such as cerebral vasospasm, cerebral infarction.

Claims (3)

1. the Nimodipine oral disintegrant tablet of treatment dementia, it is characterized in that it mainly is made up of following component: 10 gram nimodipine, 7.5 gram hydroxyethyl-celluloses, 2.5 gram gelatin, 25 gram sucrose and 65 restrain mannitol.
2. the Nimodipine oral disintegrant tablet of treatment dementia, it is characterized in that it mainly is made up of following component: 20 gram nimodipine, 1 gram hydroxyethyl-cellulose, 10 gram gelatin, 74 gram sucrose and 15 restrain mannitol.
3. the preparation method of the Nimodipine oral disintegrant tablet of claim 1 or 2 described treatment dementias is characterized in that, nimodipine is suspended in the hydroxyethyl cellulose aqueous solution, make solution A,, make solution B gelatin, mannitol and sucrose mixed dissolution, solution A and solution B are mixed, and add an amount of water dilution, fully mixing joins sharp freezing in the mould, put into the freeze dryer evacuation, and subliming up into the material bone dry, press seal, packing are the lyophilizing sheet.
CNB021254311A 2002-08-07 2002-08-07 Nimodipine oral disintegrant tablet for curing dementia and its preparation method Expired - Fee Related CN100337628C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB021254311A CN100337628C (en) 2002-08-07 2002-08-07 Nimodipine oral disintegrant tablet for curing dementia and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB021254311A CN100337628C (en) 2002-08-07 2002-08-07 Nimodipine oral disintegrant tablet for curing dementia and its preparation method

Publications (2)

Publication Number Publication Date
CN1394605A CN1394605A (en) 2003-02-05
CN100337628C true CN100337628C (en) 2007-09-19

Family

ID=4745558

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB021254311A Expired - Fee Related CN100337628C (en) 2002-08-07 2002-08-07 Nimodipine oral disintegrant tablet for curing dementia and its preparation method

Country Status (1)

Country Link
CN (1) CN100337628C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100450470C (en) * 2003-06-28 2009-01-14 南昌弘益科技有限公司 Rapid disintegrate tablet in oral and its preparation method
EA200601666A1 (en) * 2004-03-12 2007-04-27 Эгиш Дьёдьсердьяр Нирт. COMBINED PHARMACEUTICAL COMPOSITION FOR INHIBITING THE DEGREING COGNITIVE FUNCTIONS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286631A (en) * 1998-03-16 2001-03-07 山之内制药株式会社 Tablets quickly disintegrating in oral cavity and process for producing same
CN1328446A (en) * 1998-11-06 2001-12-26 埃迪克埃迪法姆药品实验室 Improved fast disintegrating tablet
CN1336827A (en) * 1999-10-12 2002-02-20 三得利株式会社 Medicinal compositions for oral use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286631A (en) * 1998-03-16 2001-03-07 山之内制药株式会社 Tablets quickly disintegrating in oral cavity and process for producing same
CN1328446A (en) * 1998-11-06 2001-12-26 埃迪克埃迪法姆药品实验室 Improved fast disintegrating tablet
CN1336827A (en) * 1999-10-12 2002-02-20 三得利株式会社 Medicinal compositions for oral use

Also Published As

Publication number Publication date
CN1394605A (en) 2003-02-05

Similar Documents

Publication Publication Date Title
RU2201216C2 (en) Rapidly cleaving pharmaceutical medicinal form
CN1709229A (en) Memantine hydrochloride orally disintegrating tablet and its preparing method
TW200824721A (en) Dry granulation binders, products, and use thereof
JP3534130B2 (en) Pharmaceutical composition
WO2010045788A1 (en) A orally disintegrating tablet of donepezil hydrochloride and the preparation method thereof
JP2008285434A (en) Quickly disintegrating tablet in oral cavity
WO2006100875A1 (en) Pharmaceutical composition
ES2359377T3 (en) COPROCESSED MICROCRYSTAL CELL AND SUGAR ALCOHOL AS EXCIPIENT FOR FORMULATIONS OF TABLETS.
CN1418631A (en) Zopiclone oral disintegrant for treating insomnia, and its prepn. method
CN100337628C (en) Nimodipine oral disintegrant tablet for curing dementia and its preparation method
JP4438121B2 (en) Intraoral rapidly disintegrating tablet and method for producing the same
CN1709246A (en) Cilnidipine orally disintegrating tablet and its preparing method
CN1394607A (en) Buxining oral disintegrant tablet for curing angina pectoris and its preparation method
CN1582955A (en) Oral disintegrants of breviscapine for diseases of cardio-cerebral blood vessels and their preparation
CN1042832A (en) Pharmaceutical composition and preparation method thereof
CN1418624A (en) Alizapride oral disintegrant for treating emesis
CN1582920A (en) Oral disintegrants of daidzein for treating cardio-vagal blood vessels diseases and their preparation
CN1418635A (en) Aspirin oral disintegrant used for treating influenza and fever, and its prepn. method
CN1418627A (en) Nitrophendipine oral disintegrant for treating angina pectoris, and its prepn. method
CN1582923A (en) Oral disintegrants of indapamine for hypertension and their preparation
CN1582917A (en) Oral disintegrants of isosorbide mononitrate and their preparation
JP4249847B2 (en) Orally disintegrating tablets containing vitamin K
CN1419910A (en) Oral cavity disintegrating tablet of chlorphenamine for treating allergy, and preparing method thereof
JP2005029557A (en) Quickly disintegrating tablet in oral cavity and method for producing the same
JPH1112162A (en) Tablet rapidly disintegrable in oral cavity and its production

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee